What FDA’s latest ibezapolstat guidance means for Acurx and the IBZ-ASPIRE trial
FDA feedback may let Acurx use one Phase 3 ibezapolstat trial for C. difficile treatment and recurrence, but evidence and funding remain decisive.
Pharma & Biotech